Notable updates, news, or analysts actions from our trading lists followed by 'Our Take'.Callon Petroleum price target raised to $16 from $6 at Citi Citi analyst Brian Downey raised the firm's price target on Callon Petroleum to $16 from $6 and keeps a Neutral rating on the shares ahead of the company's Q4 results.Our Take: A little late now! This has already doubled off of its lows. We are sitting on the sidelines now with this pick. $CPE, Callon Petroleum Company / H1 Sorrento Therapeutics initiated with a Buy at Alliance Global Partners Alliance Global Partners analyst James Molloy initiated coverage of Sorrento Therapeutics with a Buy rating and $35 price target. The company has both "one of the most active and promising pipelines in the COVID space" as well as a "potentially transformative non-opioid pain pipeline" to go with its "deep oncology pipeline," according to Molloy. He sees the potential for several significant catalysts for the stock over the next four quarters from multiple late stage clinical data read-outs and multiple potential Emergency Use Authorizations, Molloy tells investors.Our Take: Very high risk / high reward biotech pick. Looks worth a shot at its current price. Under $10 would be nice. $SRNE, Sorrento Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .